| 1 |
33833507 | Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. | 2021 |
1 |
| 2 |
33880019 | Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. | 2021 |
5 |
| 3 |
32440111 | Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. | 2020 |
1 |
| 4 |
29872288 | Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT). | 2018 |
3 |
| 5 |
28744115 | Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study. | 2017 |
1 |
| 6 |
28838685 | Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. | 2017 Nov |
1 |
| 7 |
29202767 | Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies. | 2017 Dec 4 |
6 |
| 8 |
27109816 | The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). | 2016 May |
2 |